Medical Educational Resource
We're accelerating the delivery of treatments and cures.
Updates and Emerging Questions in Duchenne Muscular Dystrophy
Activity Snapshot
This program is supported in part by an independent medical education grant from Catalyst Pharmaceuticals, Inc.
Faculty
University of Massachusetts Chan Medical School
Boston Children's Hospital and Harvard Medical School
This webinar featuring Leslie Hayes, MD, of Boston Children’s Hospital and Harvard Medical School, and Stephen Chrzanowski, MD, of University of Massachusetts Chan Medical School, will discuss newborn screening and early intervention, gene therapy approvals and considerations, and enrolling study opportunities.
Identify treatment options available to patients with DMD.
Recognize evidence-based guidelines and best practices for managing DMD.
Incorporate recent advances in clinical studies into patient care and provide guidance to patients on the benefit of and the opportunities for participation in DMD research.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and MDA. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
See full accreditation and designation statements and disclosure report here.
There is no fee to participate in this activity. Statements of credit will be awarded based on the participant's attendance.
A statement of credit will be available upon completion of an online evaluation/claim credit form:
If you have questions about this CE activity, please contact AKH Inc at wendi@akhcme.com.
Name Relationship Commercial Interest
Stephen Chrzanowski, MD: N/A, Nothing to disclose
Leslie Hayes, MD:
Consultant; Biohaven Pharmaceuticals
Researcher; Novartis pharmaceuticals, Biohaven pharmaceuticals, Vertex pharmaceuticals, Astellas pharmaceuticals
Dorothy Caputo, MA, BSN, RN - VP, Healthcare Continuing Education and Operations: N/A; Nothing to disclose
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer): N/A; Nothing to disclose
Dorothy Duffy, RPh (planner/reviewer): N/A; Nothing to disclose
Broc Pollinger, MSW, LSW, OSW-C, (planner/reviewer): N/A; Nothing to disclose
AKH Inc Staff and Planners: N/A; Nothing to disclose
MDA Staff and Planners: N/A; Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
